Aug 16, 2026 · 50 min
GLP-1 drugs reshape appetite science and metabolic medicine
Why Your Brain Thinks You're Full (Even When You're Not)
The episode connects a decades-long chain of metabolic research to drugs that may alter hunger, compulsive behavior, food economics, and biological risk.
- 1GLP-1 drugs coordinate insulin, glucagon, digestion, and brain appetite pathways rather than simply suppressing hunger.
- 2A stable peptide from Gila monster venom helped transform fragile GLP-1 biology into longer-lasting medicines.
- 3Appetite control could challenge ultra-processed food incentives while raising unresolved questions about compulsion, culture, and safety.
Don't miss
The discovery that Gila monster venom contained a durable GLP-1-like peptide shows how an unexpected biological clue helped reshape metabolic medicine.
The brief
Hannah Fry and Michael Stevens begin with the body’s narrow blood-sugar range, then show why insulin, glucagon, and digestion form a tightly linked control system.
The key discovery is GLP-1: a gut signal that boosts insulin when glucose is high, lowers glucagon, slows stomach emptying, and reaches appetite pathways in the brain.
Early GLP-1 treatments failed because the peptide broke down quickly and caused severe nausea. A more durable analogue from Gila monster venom changed the trajectory.
The hosts connect appetite-suppressing drugs to ultra-processed food design and commercial incentives, while weighing possible effects on alcohol, smoking, gambling, and other compulsions.
The episode closes on a wider tension: AI may accelerate safer, more effective medicines, but the same biological design tools could intensify new risks.
Featuring
Michael David Stevens
Gila monster
Ozempic
Wegovy
John EngListen to the full episode and explore every guest, topic, and moment on PodLume.